NCT06564207View on ClinicalTrials.gov

Fostamatinib for Treating Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Adults

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

October 31, 2026

Conditions
Acute Respiratory Distress SyndromeARDS
Interventions
DRUG

Placebo

Placebo to be given twice daily for 14 days

DRUG

Fostamatinib

Fostamatinib 150mg to be given twice daily for 14 days

Sponsors

Collaborators (1)

Rigel Pharmaceuticals
All Listed Sponsors
collaborator

Rigel Pharmaceuticals

INDUSTRY

collaborator

Biomedical Advanced Research and Development Authority

FED

lead

Inova Health Care Services

OTHER